Kejie Pharmaceuticals presented the latest research results of three CAR-T cell products at the 66th Annual Meeting of the usa Hematology Society. These include the allogeneic CAR-T cell candidate product CT0590 targeting BCMA, the autologous CAR-T cell candidate product CT071 targeting GPRC5D, and the approved autologous CAR-T cell product Saikaze® (zavoclenocabtagene autoleucel injection) targeting BCMA.The IIT concept verification study results of CT0590 showed its preliminary safety and efficacy in patients with relapsed/refractory multiple myeloma. Updated research results of CT071 demonstrated its application in the treatment of refractory/relapsed multiple myeloma. The subgroup analysis results of the LUMMICAR STUDY 1 assessed its efficacy in patients with relapsed/refractory multiple myeloma. These research results reflect Kejie Pharmaceuticals' continued innovation and progress in the...Show More

Kejie Pharmaceuticals presented the latest research results of three CAR-T cell products at the 66th Annual Meeting of the usa Hematology Society. These include the allogeneic CAR-T cell candidate product CT0590 targeting BCMA, the autologous CAR-T cell candidate product CT071 targeting GPRC5D, and the approved autologous CAR-T cell product Saikaze® (zavoclenocabtagene autoleucel injection) targeting BCMA.The IIT concept verification study results of CT0590 showed its preliminary safety and efficacy in patients with relapsed/refractory multiple myeloma. Updated research results of CT071 demonstrated its application in the treatment of refractory/relapsed multiple myeloma. The subgroup analysis results of the LUMMICAR STUDY 1 assessed its efficacy in patients with relapsed/refractory multiple myeloma. These research results reflect Kejie Pharmaceuticals' continued innovation and progress in the field of CAR-T cell therapy.Kejie Pharmaceuticals focuses on developing innovative CAR-T cell therapies for hematologic malignancies and solid tumors, with a comprehensive R&D platform from target discovery to commercial production. The company is committed to addressing the significant challenges faced by existing CAR-T cell therapies, such as improving safety, enhancing the efficacy of solid tumor treatments, and reducing treatment costs, aiming to provide innovative and differentiated cell therapies for global cancer patients.